• bioNova is a specialized life science distributor with focus on genomics, proteomics and clinical diagnostics
• Recently launched TruePrime™Single Cell WGA kit in stock for immediate distribution
• TruePrime™ is a powerful amplification tool addressing key challenges in Next Generation Sequencing
Madrid, Spain and Heidelberg, Germany, January 21 st , 2015 - SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced a collaboration agreement with bioNova cientifica, s.l. for the commercialization of the TruePrime™ Single Cell WGA kit in Spain. The recently launched product was developed by SYGNIS and is optimized for the whole genome amplification (WGA) from single cells.
Under the terms of the agreement, bioNova will promote, market, sell and support TruePrime™ Single Cell WGA kit, the first amplification kit for single cell WGA based on SYGNIS’ revolutionary novel multiple displacement amplification (MDA) technology addressing key challenges in NGS applications, increasingly demanded in fields such as oncology, pathology and clinical diagnostics.
Founded in 1987, bioNova is a specialized provider of a wide range of high quality products, technologies and instruments for the life sciences markets including genomics, proteomics, and cell biology to customers in Spain.
TruePrime™ Single Cell WGA kit is available in two formats, containing 25 or 100 reactions. Beside the European commercialization via distributors, the product is made available globally and can also be directly ordered through SYGNIS’ newly introduced TruePrime™ online shop under www.sygnis.com/shop.
About TruePrime™
TruePrime™ is the brand name of a revolutionary novel MDA technology and one of the key products in SYGNIS’ portfolio. TruePrime™ is based on the combination of the recently discovered polymerase “TthPrimPol” and the extremely processive and high-fidelity Phi29 polymerase to amplify uniformly total genomic DNA for a multitude of applications including next generation sequencing and single cell analysis. The extraordinary strand displacement capacity of the Phi29 polymerase allows TthPrimPol to generate new primers on the displaced strands that are extended by Phi29 DNA pol, resulting in exponential isothermal DNA amplification without the need of any synthetic random primers.
The resulting benefits of this innovative approach are enormous and include complete absence of common artifacts linked to the use of oligonucleotides, a reduced amplification bias in genome coverage compared to methods using random synthetic primers, a surpassing reliability as contaminating DNA is not amplified and an exquisite reproducibility when DNA is amplified from single mammalian cells. Moreover, TruePrime™ shows superior sensitivity, is easy to use and works perfectly well with all commonly used NGS platforms such as Illumina and IonTorrent.
For further information please contact:
SYGNIS AG
Pilar de la Huerta
CEO/CFO
Phone: +34 91 192 36 50
Email: pdelahuerta@sygnis.es
MC Services AG
Raimund Gabriel
Managing Partner
Phone: +49 89 210228 30
Email: raimund.gabriel@mc-services.eu
About SYGNIS AG: www.sygnis.com
Following the merger with X-Pol Biotech in 2012, SYGNIS specializes on the development and commercialization of products for DNA amplification and sequencing. SYGNIS AG, listed at the German Stock Exchange (Prime Standard segment, Tick: LIO1; ISIN: DE000A1RFM03), has a commercial product for whole genome DNA amplification, SensiPhi ® , licensed to an industry leading partner and is currently developing its own TruePrime™ product line based on its proprietary TruePrime™ technology for use in the fast growing field of Next Generation Sequencing. The first product for single cell DNA amplification was launched in January 2015.
### This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason.
